AHA Coding Clinic® for ICD-9 - 2011 Quarter 4; VOLUMES 1 & 2 NEW/REVISED CODES
Drug-induced Pancytopenia
A patient with metastatic breast cancer of the left upper-outer quadrant developed pancytopenia following chemotherapy. The patient presents to the oncologist for follow-up. The oncologist listed chemotherapy induced pancytopenia in his final diagnostic statement. What code should be assigned for chemotherapy induced pancytopenia? ...
Subscribe or sign in to view the full article.
Article Overview
This article covers an ICD-9-CM coding update for pancytopenia that became effective October 1, 2011, with emphasis on how the diagnosis category was expanded to improve specificity for drug-related cases. It is aimed at coders and billing staff who need to understand the affected diagnosis family, the revised code structure, and the general clinical context behind pancytopenia associated with chemotherapy and other drugs.
Why This Topic Matters
Accurate classification of pancytopenia affects diagnosis reporting specificity and helps distinguish chemotherapy-related cases from other drug-related or unspecified forms. The article highlights a change that impacts coding consistency and claim documentation for hematology and oncology encounters.
Article Sections
-
Effective October 1, 2011 coding update
Introduces the diagnosis family change and the date it took effect. Summarizes the reason the category was revised for greater specificity.
-
Clinical background on pancytopenia
Provides a general medical overview of pancytopenia and its relationship to bone marrow suppression. Places the coding discussion in a clinical context relevant to oncology and drug-related care.
-
ICD-9-CM classification revisions
Shows the affected diagnosis category and the revised subcategory structure. Includes the code family references discussed in the article.
-
Clinical example and coding question
Presents a patient scenario involving cancer treatment and follow-up care. Frames the coding question addressed by the article without reproducing the answer logic.
-
Coding guidance note
Summarizes the general reporting guidance discussed for this diagnosis scenario. References the related adverse-effect code family mentioned in the article.
What You Will Learn
- How the pancytopenia diagnosis category was updated in ICD-9-CM
- Which broad types of pancytopenia the revised structure distinguishes
- The clinical context commonly associated with drug-induced pancytopenia
- What kind of encounter scenario the article uses to illustrate the coding issue
- How the article frames related diagnosis and adverse-effect reporting at a high level
Who Should Read This
- Medical coders
- Coding auditors
- Oncology billing staff
- Health information management professionals
- Clinical documentation staff
Codes Discussed
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com